Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOLENE AP-65 vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DOLENE AP-65 is a combination of dipyrone (metamizole) and propantheline. Dipyrone is a non-opioid analgesic and antipyretic that acts centrally and peripherally via inhibition of cyclooxygenase and activation of the endocannabinoid system. Propantheline is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and spasm.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Pain relief (visceral, colicky),Postoperative pain,Fever reduction
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
DOLENE AP-65 (propoxyphene napsylate 100 mg and acetaminophen 650 mg). Adult: 1 tablet orally every 4 hours as needed for pain. Maximum: 6 tablets per day.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
2-3 hours in adults with normal hepatic function; prolonged in hepatic impairment (up to 5-10 hours) and in neonates (up to 3-5 hours)
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Dipyrone is metabolized primarily in the liver via CYP450 enzymes (CYP2C9, CYP2C19) to active metabolites (4-methylaminoantipyrine and 4-aminoantipyrine). Propantheline is metabolized hepatic via ester hydrolysis and conjugation.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Renal: 90% (50% as acetaminophen glucuronide, 30% as sulfate, 5% as cysteine, 3% as unchanged drug, 2% as other metabolites); Fecal: <5%
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
10-25% bound to plasma proteins (mainly albumin) at therapeutic concentrations; binding is minimal and not saturable
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
0.9-1.0 L/kg; indicates distribution into total body water; slightly higher in females and elderly
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral: 85-90% (first-pass metabolism reduces bioavailability slightly); Rectal: 80-90%
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Contraindicated in severe renal impairment (e GFR <30 m L/min). For moderate impairment (e GFR 30-59 m L/min): extend dosing interval to every 8 hours. Monitor for propoxyphene accumulation.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce dose by 50% and monitor liver function. Use with caution in class A.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Contraindicated in children under 12 years due to risk of respiratory depression. For adolescents 12-18 years: administer as per adult dosing if clinically appropriate; monitor closely.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Start with one tablet every 6 hours due to increased sensitivity and reduced clearance. Maximum: 4 tablets per day. Avoid in patients with renal impairment, respiratory compromise, or concurrent CNS depressants.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Dipyrone may cause agranulocytosis, a severe and potentially fatal decrease in white blood cells. Use is contraindicated in patients with known hypersensitivity to dipyrone or other pyrazolones.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Risk of agranulocytosis with dipyrone; monitor blood counts. Anticholinergic effects of propantheline (e.g., urinary retention, constipation, blurred vision). Caution in elderly, renal/hepatic impairment, and history of gastrointestinal obstruction.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity to dipyrone or propantheline,History of agranulocytosis,Bone marrow suppression,Gastrointestinal obstruction,Myasthenia gravis,Narrow-angle glaucoma,Prostatic hypertrophy
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Avoid alcohol and grapefruit juice (may alter tramadol metabolism). High-fat meals may delay absorption but not overall effect. No other significant food interactions.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
First trimester: Propoxyphene (component of Dolene AP-65) is classified as FDA Pregnancy Category C; animal studies show fetal harm but no adequate human studies. Second/third trimester: Prolonged use may cause opioid withdrawal in neonate (neonatal abstinence syndrome). Acetaminophen (AP-65 component) is generally considered low risk but high doses may be hepatotoxic. Avoid use during pregnancy unless benefit outweighs risk.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Propoxyphene is excreted in breast milk; M/P ratio approximately 0.5. Low levels in milk; however, due to risk of neonatal opioid toxicity and respiratory depression, caution advised. Acetaminophen is considered compatible with breastfeeding. Consider alternative analgesics.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No specific dose adjustments recommended; however, propoxyphene is generally avoided in pregnancy due to neonatal withdrawal risk. Acetaminophen dose adjustments not typically needed, but monitor for hepatotoxicity, as pregnancy may alter hepatic metabolism. Use lowest effective dose for shortest duration.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
DOLENE AP-65 is a combination of tramadol (opioid analgesic) and acetaminophen. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcoholism. Maximum daily acetaminophen dose is 4 g; beware of hidden sources. Tramadol may lower seizure threshold; use cautiously in epilepsy or head trauma. CYP2D6 poor metabolizers may have reduced efficacy.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Do not exceed 8 tablets per day due to acetaminophen liver toxicity risk.,Avoid alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,May cause drowsiness or dizziness; avoid driving until effects are known.,Report signs of serotonin syndrome (confusion, rapid heart rate, fever) or seizures.,Do not stop abruptly to prevent withdrawal; taper under doctor guidance.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOLENE AP-65 vs ANEXSIA 7.5/650, answered by our medical review team.
DOLENE AP-65 is a Opioid Analgesic Combination that works by DOLENE AP-65 is a combination of dipyrone (metamizole) and propantheline. Dipyrone is a non-opioid analgesic and antipyretic that acts centrally and peripherally via inhibition of cyclooxygenase and activation of the endocannabinoid system. Propantheline is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and spasm.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOLENE AP-65 and ANEXSIA 7.5/650 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOLENE AP-65 is: DOLENE AP-65 (propoxyphene napsylate 100 mg and acetaminophen 650 mg). Adult: 1 tablet orally every 4 hours as needed for pain. Maximum: 6 tablets per day.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOLENE AP-65 and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOLENE AP-65 is classified as Category C. First trimester: Propoxyphene (component of Dolene AP-65) is classified as FDA Pregnancy Category C; animal studies show fetal harm but no adequate human studies. Second/third trim. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.